Opko Health Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect eleven director nominees named in the proxy statement to serve until the 2027 annual meeting or until their successors are elected and qualified.

2. 2

   Approval of OPKO Health, Inc. 2026 Equity Incentive Plan

   ManagementBoard: FOR

   Approve the OPKO Health, Inc. 2026 Equity Incentive Plan to replace the 2016 plan and reserve shares for equity awards to attract, retain and incentivize employees, directors and consultants.

   More detail

   This proposal asks shareholders to approve the OPKO Health, Inc. 2026 Equity Incentive Plan, which the Board and Compensation Committee adopted to replace the existing 2016 plan and to provide a share reserve (30,000,000 initial shares plus recycling rules) to grant equity-based awards to employees, directors and consultants. Management seeks shareholder approval to ensure continued ability to offer long-term equity incentives that align employee interests with stockholders, permit tax-qualified incentive stock options where applicable, and maintain competitive compensation practices. The plan includes governance-oriented limits—no evergreen provision, restrictions on liberal share recycling, prohibition on repricing without shareholder approval, minimum vesting requirements (one year subject to exceptions), and clawback provisions—which management presents as protective of shareholder interests. The plan also specifies per-person limitations for incentive stock options, procedures for adjustments in corporate events, and administrative authority vested in the Compensation Committee. Approval is framed as necessary because, without a new plan, the company would face materially limited ability to use equity compensation given outstanding awards under the prior plan and a depleted share pool. The Board recommends a FOR vote, citing the plan’s role in attracting, motivating and retaining talent, aligning compensation with long-term performance, and incorporating features intended to address governance concerns and shareholder protection. Key contextual factors include the company’s complex mix of pharmaceuticals, diagnostics and services businesses, the use of performance awards and restrictions to link pay to outcomes, and the practical need to replenish the equity award capacity to support hundreds of eligible employees and non-employee directors. While the Committee retains significant discretion over awards, the plan’s enumerated safeguards (no repricing without approval, limited recycling, clawback and minimum vesting) are management’s rationale for shareholder support.

3. 3

   Non‑binding Advisory Resolution Regarding Named Executive Officer Compensation (“Say on Pay”

   ManagementBoard: FOR

   An advisory (non-binding) vote to approve the compensation of the Company's named executive officers as disclosed in the proxy statement, including the Compensation Discussion and Analysis and compensation tables.

   More detail

   This advisory proposal asks shareholders to approve, on a non-binding basis, the compensation paid to the Company’s named executive officers as disclosed in the proxy statement. Management frames the vote as a required advisory vote under Section 14A of the Exchange Act and explains that the compensation program is designed to attract and retain executives, be market-competitive, tie incentives to corporate performance, and be cost-effective via base salary, discretionary annual bonuses and equity awards. The Board recommends a FOR vote but notes the result is advisory only; the Compensation Committee will take the outcome into account when considering future executive compensation arrangements. The filing references prior shareholder support (approximately 98% in 2025) as context for the program’s acceptance and indicates ongoing engagement with stockholders on compensation and governance topics. For analysts, the key tradeoffs include the program’s reliance on discretionary bonuses and committee discretion in equity grants versus the structural safeguards described elsewhere (e.g., clawback policy, minimum vesting for equity awards, and pay-for-performance disclosure).

4. 4

   Ratification of Appointment of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Upcoming shareholder meetings at Opko Health Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Opko Health Inc 2026 annual meeting?

Opko Health Inc (OPK) holds its 2026 annual shareholder meeting on Thursday, June 18, 2026.

What is the record date for the Opko Health Inc 2026 meeting?

The record date for the Opko Health Inc 2026 meeting is Monday, April 20, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Opko Health Inc's 2026 meeting?

The board is presenting 11 director nominees at the Opko Health Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Opko Health Inc 2026 meeting?

Shareholders will vote on 4 proposals at the Opko Health Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.